UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 23, 2014
Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-30929 | 13-4087132 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
The 2014 annual meeting of stockholders of Keryx Biopharmaceuticals, Inc. (“Keryx”) was held on June 23, 2014. The following matters were voted on by the stockholders: the election of directors, the ratification of the appointment of UHY LLP as Keryx’s independent registered public accounting firm for the year ending December 31, 2014, and the advisory vote on the compensation of named executive officers. At the meeting, Ron Bentsur, Kevin J. Cameron, Joseph Feczko, M.D., Wyche Fowler, Jr., Jack Kaye, Daniel Regan, and Michael P. Tarnok were re-elected to the Board.
The vote with respect to each nominee is set forth below:
| Nominee |
Total Votes For | Total Votes Withheld | Broker Non-Votes | |||||||||
| Ron Bentsur |
36,690,444 | 9,553,767 | 29,180,554 | |||||||||
| Kevin J. Cameron |
45,939,778 | 304,433 | 29,180,554 | |||||||||
| Joseph Feczko, M.D. |
45,936,950 | 307,261 | 29,180,554 | |||||||||
| Wyche Fowler, Jr. |
45,910,331 | 333,880 | 29,180,554 | |||||||||
| Jack Kaye |
45,933,403 | 310,808 | 29,180,554 | |||||||||
| Daniel Regan |
45,974,595 | 269,616 | 29,180,554 | |||||||||
| Michael P. Tarnok |
45,938,935 | 305,276 | 29,180,554 | |||||||||
The vote with respect to the ratification of the appointment of UHY LLP as Keryx’s independent registered public accounting firm for the year ending December 31, 2014, is set forth below:
| Total Votes For |
Total Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 74,437,251 | 207,723 | 779,791 | 0 | |||||||||||
The vote with respect to the advisory vote on the compensation of Keryx’s named executive officers is set forth below:
| Total Votes For |
Total Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 44,916,231 | 1,129,587 | 198,393 | 29,180,554 | |||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Keryx Biopharmaceuticals, Inc. | ||||||
| (Registrant) | ||||||
| Date: June 24, 2014 | By: | /s/ James F. Oliviero | ||||
| James F. Oliviero | ||||||
| Chief Financial Officer | ||||||